= Not Reported; N = Sample Size; SD = Standard Deviation

Table G-18. Change in bone mineral density from baseline in studies comparing older versus newer antiepileptic drugs

Study year / Group / N / Bone Mineral Density
(gm/cm2)
Mean (SD) / Bone Mineral Density
(gm/cm2)
Mean (SD) / Bone Mineral Density
(gm/cm2)
Mean (SD) / Bone Mineral Density
(gm/cm2)
Mean (SD) / Bone Mineral Density
(gm/cm2)
Mean (SD) /
Babayigit, 2006 / Carbamazepine / 23 / Lumbar Vertebrae 1
0.648 (0.162) / Lumbar Vertebrae 2
0.72 (0.173) / Lumbar Vertebrae 3
0.732 (0.164) / Lumbar Vertebrae 4
0.744 (0.188) / Lumbar Vertebrae Total
0.665 (0.199)
Valproic Acid / 31 / Lumbar Vertebrae 1
0.596 (0.191) / Lumbar Vertebrae 2
0.666 (0.213) / Lumbar Vertebrae 3
0.692 (0.206) / Lumbar Vertebrae 4
0.694 (0.194) / Lumbar Vertebrae Total
0.665 (0.199)
Oxcarbazepine / 14 / Lumbar Vertebrae 1
0.679 (0.188) / Lumbar Vertebrae 2
0.747 (0.188) / Lumbar Vertebrae 3
0.771 (0.196) / Lumbar Vertebrae 4
0.767 (0.195) / Lumbar Vertebrae Total
0.744 (0.188)
Pack, 2008 / Carbamazepine / 41 / Lumbar Spine
Baseline: 1.016 (0.12)
1 year: 1.021 (0.12) / Femoral Neck
Baseline: 0.792 (0.10)
1 year: 0.794 (0.10) / Total Hip
Baseline: 0.889 (0.12)
1 year: 0.892 (0.11) / - / -
Valproate / 14 / Lumbar Spine
Baseline: 0.998 (0.15)
1 year: 0.999 (0.16) / Femoral Neck
Baseline: 0.838 (0.18)
1 year: 0.843 (0.18) / Total Hip
Baseline: 0.926 (0.18)
1 year: 0.931 (0.19) / - / -
Phenytoin / 15 / Lumbar Spine
Baseline: 1.073 (0.16)
1 year: 1.077 (0.17) / Femoral Neck
Baseline: 0.871 (0.18)
1 year: 0.849 (0.16) / Total Hip
Baseline: 0.962 (0.15)
1 year: 0.0.961 (0.15) / - / -
Lamotrigine / 23 / Lumbar Spine
Baseline: 1.068 (0.11)
1 year: 1.066 (0.09) / Femoral Neck
Baseline: 0.835 (0.11)
1 year: 0.828 (0.11) / Total Hip
Baseline: 0.922 (0.11)
1 year: 0.920 (0.11) / - / -

- = not reported; N = sample size; SD = standard deviation